Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 69 citing articles:

Natural killer cells in antitumour adoptive cell immunotherapy
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature reviews. Cancer (2022) Vol. 22, Iss. 10, pp. 557-575
Open Access | Times Cited: 467
Forks in the road for CAR T and CAR NK cell cancer therapies
Oula K. Dagher, Avery D. Posey
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 1994-2007
Closed Access | Times Cited: 50
NK cell-based tumor immunotherapy
Hao Zhang, Yang Li, Tingting Wang, et al.
Bioactive Materials (2023) Vol. 31, pp. 63-86
Open Access | Times Cited: 44
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Alessandra Cesano, Ryan C. Augustin, Luigi Barrea, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e008876-e008876
Open Access | Times Cited: 2
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Shweta Joshi, Andrew B. Sharabi
Pharmacology & Therapeutics (2022) Vol. 235, pp. 108114-108114
Open Access | Times Cited: 52
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Alain E. Andrea, Andrada Chiron, Sarah Mallah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression
Yunna Chen, Qianqian Zhou, Zongfang Jia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 3834-3854
Open Access | Times Cited: 12
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells
Jaya Lakshmi Thangaraj, Michael Coffey, Edith Lopez, et al.
Cell stem cell (2024) Vol. 31, Iss. 9, pp. 1327-1343.e5
Closed Access | Times Cited: 11
Epstein–Barr Virus—Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies
Marcus Bauer, Simon Jasinski‐Bergner, Ofer Mandelboim, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5189-5189
Open Access | Times Cited: 53
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Katarzyna Starska
Cancers (2023) Vol. 15, Iss. 6, pp. 1642-1642
Open Access | Times Cited: 21
Therapeutic effect of small extracellular vesicles from cytokine-induced memory-like natural killer cells on solid tumors
Ying‐Hong Shi, Yanxia Chen, Yi Wang, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Therapeutic utility of engineered myeloid cells in the tumor microenvironment
Alessandro Canella, Prajwal Rajappa
Cancer Gene Therapy (2023) Vol. 30, Iss. 7, pp. 964-972
Open Access | Times Cited: 13
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 13
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy – obstacles and perspectives
Jiřina Procházková, Zuzana Kahounová, Jan Vondráček, et al.
Transcription (2024), pp. 1-20
Closed Access | Times Cited: 5
Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges
Jun Kong, Mohammad Auwal Sa’ad, Hema Manusri Vijayan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
Xia Yang, Chunye Huang, Min Zhong, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer
Manh-Cuong Vo, Van‐Tan Nguyen, Van-Dinh-Huan Tran, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
STAT3 Signaling Pathway in Health and Disease
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Zhiquan Qiu, Zhengrui Li, Cangang Zhang, et al.
Aging and Disease (2025)
Open Access
Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B
Frederik Fabian Feigl, Anika Stahringer, Matthias Peindl, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3129-3129
Open Access | Times Cited: 12
Myeloid-Derived Suppressor–Cell Dynamics Control Outcomes in the Metastatic Niche
Jesse Kreger, Evanthia T. Roussos Torres, Adam L. MacLean
Cancer Immunology Research (2023) Vol. 11, Iss. 5, pp. 614-628
Open Access | Times Cited: 12
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
Tatiana V. Kudling, James H.A. Clubb, Santeri A. Pakola, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Massimo Claudio Fantini, Philip M. Arlen, Kwong Y. Tsang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy
Peng Peng, Yue Lou, Shicheng Wang, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005769-e005769
Open Access | Times Cited: 17
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top